Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Former President Joe Biden was diagnosed with an “aggressive form” of prostate cancer that has a five-year survival rate of between 30% and 40%. The former president’s prostate cancer is characterized ...

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior ...

Doctors followed standard testing guidelines, which recommend discontinuing screenings for men over 70 years old. Should that ...

Figure 3: Immunohistochemistry (IHC) and Immunofluorescence (IF) analysis of MD2 expression and immune cell infiltration in prostate cancer tissues. (Upper panel) Representative IF images showing ...

A man whose twin died with prostate cancer has said the news that tens of thousands more black men will be invited to ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

Saliva IL6 Upregulation As a Potential Indicator of Tobacco-Smoke Associated OSCC and Disease Progression and the Association of Saliva RELA(p65) Upregulation With OSCC Local Invasion in Non-Smokers ...

High-risk localized and locally advanced prostate cancer patients treated with apalutamide—a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and ...

Patients with metastatic hormone-sensitive prostate cancer and baseline bone pain at diagnosis have worse overall survival compared to those without bone pain, a post hoc study found. Patients with ...